Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday

Annovis Bio (NYSE:ANVS) is projected to release its Q4 2025 results before the market opens on Friday, March 20th. Analysts expect Annovis Bio to post earnings of ($0.3084) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Annovis Bio Price Performance

NYSE ANVS opened at $2.46 on Friday. The company’s fifty day moving average is $2.83 and its two-hundred day moving average is $2.83. Annovis Bio has a 52-week low of $1.11 and a 52-week high of $5.50. The firm has a market capitalization of $65.08 million, a price-to-earnings ratio of -1.71 and a beta of 1.32.

Institutional Trading of Annovis Bio

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Annovis Bio by 5.9% in the third quarter. Vanguard Group Inc. now owns 738,003 shares of the company’s stock valued at $1,528,000 after acquiring an additional 41,239 shares during the period. Marshall Wace LLP bought a new position in shares of Annovis Bio during the fourth quarter valued at $2,511,000. Geode Capital Management LLC lifted its holdings in shares of Annovis Bio by 20.6% during the fourth quarter. Geode Capital Management LLC now owns 222,132 shares of the company’s stock valued at $769,000 after acquiring an additional 37,978 shares during the period. State Street Corp boosted its stake in shares of Annovis Bio by 92.6% in the 4th quarter. State Street Corp now owns 74,035 shares of the company’s stock valued at $256,000 after purchasing an additional 35,600 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Annovis Bio in the 4th quarter valued at $215,000. Institutional investors and hedge funds own 15.83% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Annovis Bio in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Annovis Bio presently has a consensus rating of “Hold” and a consensus price target of $13.50.

About Annovis Bio

Annovis Bio, Inc (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions.

The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients.